About Qantgene
Qantgene is a company based in Berkeley (United States) founded in 2015.. Qantgene has raised $12.13 million across 3 funding rounds from investors including Vikor Scientific. Qantgene offers products and services including Qx, Genomic Tumor Profiling, and Qx Plus. Qantgene operates in a competitive market with competitors including GRAIL, Color, Earli, RainDance and NovellusDx, among others.
- Headquarter Berkeley, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Quantgene Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.13 M (USD)
in 3 rounds
-
Latest Funding Round
$6 M (USD), Series B
Feb 18, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Qantgene
Qantgene offers a comprehensive portfolio of products and services, including Qx, Genomic Tumor Profiling, and Qx Plus. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for early cancer detection using genomics and intelligence.
Service for tumor analysis to improve cancer care outcomes.
Combines genomics with imaging for advanced cancer detection.
Unlock access to complete
Funding Insights of Qantgene
Qantgene has successfully raised a total of $12.13M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $6.0M
-
First Round
First Round
(09 Jan 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Series B - Qantgene | Valuation | Vikor Scientific |
|
| Oct, 2017 | Amount | Series A - Qantgene | Valuation |
investors |
|
| Jan, 2017 | Amount | Seed - Qantgene | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Qantgene
Qantgene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Vikor Scientific. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides rapid molecular diagnostics and testing for pathogens in healthcare settings.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Qantgene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Qantgene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Qantgene Comparisons
Competitors of Qantgene
Qantgene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Earli, RainDance and NovellusDx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Cancer care is delivered through a virtual clinic by Color.
|
|
| domain | founded_year | HQ Location |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| domain | founded_year | HQ Location |
Developer of nucleic acid detection and quantification systems
|
|
| domain | founded_year | HQ Location |
Developer of technology for precision cancer diagnosis and therapies
|
|
| domain | founded_year | HQ Location |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Qantgene
Frequently Asked Questions about Qantgene
When was Qantgene founded?
Qantgene was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Qantgene located?
Qantgene is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Is Qantgene a funded company?
Qantgene is a funded company, having raised a total of $12.13M across 3 funding rounds to date. The company's 1st funding round was a Seed of $980K, raised on Jan 09, 2017.
What does Qantgene do?
Qantgene was founded in 2015 and is based in Berkeley, United States, within the biotechnology sector. Blood tests for cancer screening and early disease detection are developed and provided. The GRIFFIN Deep Genomics platform is employed, integrating precision sequencing, software, and AI to analyze cell-free DNA fragments. Operations focus on profiling genetic material to support diagnostic applications in healthcare.
What products or services does Qantgene offer?
Qantgene offers Qx, Genomic Tumor Profiling, and Qx Plus.
Who are Qantgene's investors?
Qantgene has 1 investor. Key investors include Vikor Scientific.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.